RAQUEL
RIVERA DÍAZ
Profesora asociada de Ciencias de la Salud
![Foto de Enrique](/img/nophoto.png)
Enrique
Herrera Ceballos
Publicaciones en las que colabora con Enrique Herrera Ceballos (25)
2023
-
Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: Results from a 52-Week Open-Label Phase IV Clinical Trial (DIMESKIN 1)
Dermatology and Therapy, Vol. 13, Núm. 1, pp. 329-345
2022
-
Moderate to Severe Psoriasis in Pediatric and Young Patients: The BIOBADADERM Registry Experience
Actas Dermo-Sifiliograficas, Vol. 113, Núm. 4, pp. 401-406
-
The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry
Journal of Dermatological Treatment, Vol. 33, Núm. 4, pp. 2110-2117
2021
-
Effect of Sex in Systemic Psoriasis Therapy: Differences in Prescription, Effectiveness and Safety in the BIOBADADERM Prospective Cohort
Acta dermato-venereologica, Vol. 101, Núm. 1, pp. adv00354
-
Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis
Journal of the American Academy of Dermatology, Vol. 84, Núm. 2, pp. 513-517
2020
-
Changing Trends in Drug Prescription and Causes of Treatment Discontinuation of First Biologic Over Ten Years in Psoriasis in the Spanish Biobadaderm Registry
Actas Dermo-Sifiliograficas, Vol. 111, Núm. 9, pp. 752-760
-
Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry
Journal of the American Academy of Dermatology, Vol. 83, Núm. 1, pp. 139-150
-
The risk of urinary tract infections in patients with psoriasis on systemic medications in Biobadaderm Registry: A prospective cohort study
Journal of the American Academy of Dermatology, Vol. 82, Núm. 3, pp. 738-741
2019
2018
-
Change over time in the rates of adverse events in patients receiving systemic therapy for psoriasis: A cohort study
Journal of the American Academy of Dermatology, Vol. 78, Núm. 4, pp. 798-800
-
Description of Patients Treated with Biologic Drugs as First-Line Systemic Therapy in the BIOBADADERM Registry Between 2008 and 2016
Actas Dermo-Sifiliograficas, Vol. 109, Núm. 7, pp. 617-623
2017
-
Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm
Journal of the European Academy of Dermatology and Venereology, Vol. 31, Núm. 10, pp. 1700-1708
-
Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. Biobadaderm registry
Journal of the European Academy of Dermatology and Venereology, Vol. 31, Núm. 6, pp. 1021-1028
-
Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry
Journal of Investigative Dermatology, Vol. 137, Núm. 2, pp. 313-321
-
Management of Biologic Therapy in Moderate to Severe Psoriasis in Surgical Patients: Data From the Spanish Biobadaderm Registry
Actas dermo-sifiliograficas, Vol. 108, Núm. 1, pp. 52-58
-
Management of Biologic Therapy in Moderate to Severe Psoriasis in Surgical Patients: Data From the Spanish Biobadaderm Registry
Actas Dermo-Sifiliograficas, Vol. 108, Núm. 1, pp. 52-58
2016
-
Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort
Journal of Dermatological Treatment, Vol. 27, Núm. 3, pp. 203-209
-
Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis
Journal of the European Academy of Dermatology and Venereology, Vol. 30, Núm. 11, pp. 1942-1950
2015
-
Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time
Actas Dermo-Sifiliograficas, Vol. 106, Núm. 8, pp. 638-643
-
Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time
Actas dermo-sifiliograficas, Vol. 106, Núm. 8, pp. 638-643